 Cerebellar Neoplasms
"Cerebellar Neoplasms" is a descriptor in the National Library of Medicine's controlled vocabulary thesaurus,
MeSH (Medical Subject Headings). Descriptors are arranged in a hierarchical structure,
which enables searching at various levels of specificity.
Primary or metastatic neoplasms of the CEREBELLUM. Tumors in this location frequently present with ATAXIA or signs of INTRACRANIAL HYPERTENSION due to obstruction of the fourth ventricle. Common primary cerebellar tumors include fibrillary ASTROCYTOMA and cerebellar HEMANGIOBLASTOMA. The cerebellum is a relatively common site for tumor metastases from the lung, breast, and other distant organs. (From Okazaki & Scheithauer, Atlas of Neuropathology, 1988, p86 and p141)
| Descriptor ID |
D002528
|
| MeSH Number(s) |
C04.588.614.250.195.411.211 C10.228.140.211.500.200 C10.228.140.252.200 C10.551.240.250.400.300
|
| Concept/Terms |
Cerebellar Neoplasms- Cerebellar Neoplasms
- Cerebellar Tumors
- Cerebellar Tumor
- Tumor, Cerebellar
- Neoplasms, Cerebellar
- Cerebellar Neoplasm
- Neoplasm, Cerebellar
Cerebellar Neoplasms, Primary- Cerebellar Neoplasms, Primary
- Cerebellar Neoplasm, Primary
- Primary Cerebellar Neoplasm
- Primary Cerebellar Neoplasms
- Primary Neoplasms, Cerebellum
- Cerebellum Primary Neoplasm
- Cerebellum Primary Neoplasms
- Neoplasm, Cerebellum Primary
- Primary Neoplasm, Cerebellum
- Neoplasms, Cerebellar, Primary
Benign Cerebellar Neoplasms- Benign Cerebellar Neoplasms
- Benign Cerebellar Neoplasm
- Cerebellar Neoplasm, Benign
- Neoplasm, Benign Cerebellar
- Neoplasms, Cerebellar, Benign
- Cerebellar Neoplasms, Benign
Cerebellar Cancer- Cerebellar Cancer
- Cancer, Cerebellar
- Cerebellar Cancers
- Cerebellar Neoplasms, Malignant
- Neoplasms, Cerebellar, Malignant
- Malignant Cerebellar Neoplasms
- Cerebellar Neoplasm, Malignant
- Malignant Cerebellar Neoplasm
- Neoplasm, Malignant Cerebellar
|
Below are MeSH descriptors whose meaning is more general than "Cerebellar Neoplasms".
Below are MeSH descriptors whose meaning is more specific than "Cerebellar Neoplasms".
This graph shows the total number of publications written about "Cerebellar Neoplasms" by people in this website by year, and whether "Cerebellar Neoplasms" was a major or minor topic of these publications.
To see the data from this visualization as text, click here.
| Year | Major Topic | Minor Topic | Total |
|---|
| 1991 | 2 | 0 | 2 | | 1993 | 3 | 0 | 3 | | 1994 | 1 | 0 | 1 | | 1996 | 1 | 0 | 1 | | 2003 | 0 | 1 | 1 | | 2004 | 1 | 0 | 1 | | 2007 | 1 | 0 | 1 | | 2009 | 1 | 0 | 1 | | 2010 | 1 | 0 | 1 | | 2012 | 9 | 0 | 9 | | 2014 | 2 | 0 | 2 | | 2015 | 3 | 0 | 3 | | 2016 | 2 | 0 | 2 | | 2018 | 3 | 0 | 3 | | 2019 | 3 | 1 | 4 | | 2020 | 3 | 0 | 3 | | 2021 | 2 | 0 | 2 |
To return to the timeline, click here.
Below are the most recent publications written about "Cerebellar Neoplasms" by people in Profiles.
-
Katsushima K, Lee B, Kunhiraman H, Zhong C, Murad R, Yin J, Liu B, Garancher A, Gonzalez-Gomez I, Monforte HL, Stapleton S, Vibhakar R, Bettegowda C, Wechsler-Reya RJ, Jallo G, Raabe E, Eberhart CG, Perera RJ. The long noncoding RNA lnc-HLX-2-7 is oncogenic in Group 3 medulloblastomas. Neuro Oncol. 2021 04 12; 23(4):572-585.
-
Skowron P, Farooq H, Cavalli FMG, Morrissy AS, Ly M, Hendrikse LD, Wang EY, Djambazian H, Zhu H, Mungall KL, Trinh QM, Zheng T, Dai S, Stucklin ASG, Vladoiu MC, Fong V, Holgado BL, Nor C, Wu X, Abd-Rabbo D, Bérubé P, Wang YC, Luu B, Suarez RA, Rastan A, Gillmor AH, Lee JJY, Zhang XY, Daniels C, Dirks P, Malkin D, Bouffet E, Tabori U, Loukides J, Doz FP, Bourdeaut F, Delattre OO, Masliah-Planchon J, Ayrault O, Kim SK, Meyronet D, Grajkowska WA, Carlotti CG, de Torres C, Mora J, Eberhart CG, Van Meir EG, Kumabe T, French PJ, Kros JM, Jabado N, Lach B, Pollack IF, Hamilton RL, Rao AAN, Giannini C, Olson JM, Bognár L, Klekner A, Zitterbart K, Phillips JJ, Thompson RC, Cooper MK, Rubin JB, Liau LM, Garami M, Hauser P, Li KKW, Ng HK, Poon WS, Yancey Gillespie G, Chan JA, Jung S, McLendon RE, Thompson EM, Zagzag D, Vibhakar R, Ra YS, Garre ML, Schüller U, Shofuda T, Faria CC, López-Aguilar E, Zadeh G, Hui CC, Ramaswamy V, Bailey SD, Jones SJ, Mungall AJ, Moore RA, Calarco JA, Stein LD, Bader GD, Reimand J, Ragoussis J, Weiss WA, Marra MA, Suzuki H, Taylor MD. The transcriptional landscape of Shh medulloblastoma. Nat Commun. 2021 03 19; 12(1):1749.
-
Milgrom SA, Spratt DE. Association or Causality: Does Whole Brain Proton Radiotherapy Not Impact IQ? J Clin Oncol. 2020 07 01; 38(19):2211-2212.
-
Kanchan RK, Perumal N, Atri P, Chirravuri Venkata R, Thapa I, Klinkebiel DL, Donson AM, Perry D, Punsoni M, Talmon GA, Coulter DW, Boue' DR, Snuderl M, Nasser MW, Batra SK, Vibhakar R, Mahapatra S. MiR-1253 exerts tumor-suppressive effects in medulloblastoma via inhibition of CDK6 and CD276 (B7-H3). Brain Pathol. 2020 07; 30(4):732-745.
-
Moreira DC, Venkataraman S, Subramanian A, Desisto J, Balakrishnan I, Prince E, Pierce A, Griesinger A, Green A, Eberhardt CG, Foreman NK, Vibhakar R. Targeting MYC-driven replication stress in medulloblastoma with AZD1775 and gemcitabine. J Neurooncol. 2020 May; 147(3):531-545.
-
Ocasio J, Babcock B, Malawsky D, Weir SJ, Loo L, Simon JM, Zylka MJ, Hwang D, Dismuke T, Sokolsky M, Rosen EP, Vibhakar R, Zhang J, Saulnier O, Vladoiu M, El-Hamamy I, Stein LD, Taylor MD, Smith KS, Northcott PA, Colaneri A, Wilhelmsen K, Gershon TR. scRNA-seq in medulloblastoma shows cellular heterogeneity and lineage expansion support resistance to SHH inhibitor therapy. Nat Commun. 2019 12 20; 10(1):5829.
-
de Medeiros CB, Moxon-Emre I, Scantlebury N, Malkin D, Ramaswamy V, Decker A, Law N, Kumabe T, Leonard J, Rubin J, Jung S, Kim SK, Gupta N, Weiss W, Faria CC, Vibhakar R, Lafay-Cousin L, Chan J, Kros JM, Janzen L, Taylor MD, Bouffet E, Mabbott DJ. Medulloblastoma has a global impact on health related quality of life: Findings from an international cohort. Cancer Med. 2020 01; 9(2):447-459.
-
Suzuki H, Kumar SA, Shuai S, Diaz-Navarro A, Gutierrez-Fernandez A, De Antonellis P, Cavalli FMG, Juraschka K, Farooq H, Shibahara I, Vladoiu MC, Zhang J, Abeysundara N, Przelicki D, Skowron P, Gauer N, Luu B, Daniels C, Wu X, Forget A, Momin A, Wang J, Dong W, Kim SK, Grajkowska WA, Jouvet A, Fèvre-Montange M, Garrè ML, Nageswara Rao AA, Giannini C, Kros JM, French PJ, Jabado N, Ng HK, Poon WS, Eberhart CG, Pollack IF, Olson JM, Weiss WA, Kumabe T, López-Aguilar E, Lach B, Massimino M, Van Meir EG, Rubin JB, Vibhakar R, Chambless LB, Kijima N, Klekner A, Bognár L, Chan JA, Faria CC, Ragoussis J, Pfister SM, Goldenberg A, Wechsler-Reya RJ, Bailey SD, Garzia L, Morrissy AS, Marra MA, Huang X, Malkin D, Ayrault O, Ramaswamy V, Puente XS, Calarco JA, Stein L, Taylor MD. Recurrent noncoding U1 snRNA mutations drive cryptic splicing in SHH medulloblastoma. Nature. 2019 10; 574(7780):707-711.
-
Cormerais Y, Pagnuzzi-Boncompagni M, Schrötter S, Giuliano S, Tambutté E, Endou H, Wempe MF, Pagès G, Pouysségur J, Picco V. Inhibition of the amino-acid transporter LAT1 demonstrates anti-neoplastic activity in medulloblastoma. J Cell Mol Med. 2019 04; 23(4):2711-2718.
-
Bakhshinyan D, Venugopal C, Adile AA, Garg N, Manoranjan B, Hallett R, Wang X, Mahendram S, Vora P, Vijayakumar T, Subapanditha M, Singh M, Kameda-Smith MM, Qazi M, McFarlane N, Mann A, Ajani OA, Yarascavitch B, Ramaswamy V, Farooq H, Morrissy S, Cao L, Sydorenko N, Baiazitov R, Du W, Sheedy J, Weetall M, Moon YC, Lee CS, Kwiecien JM, Delaney KH, Doble B, Cho YJ, Mitra S, Kaplan D, Taylor MD, Davis TW, Singh SK. BMI1 is a therapeutic target in recurrent medulloblastoma. Oncogene. 2019 03; 38(10):1702-1716.
|
People  People who have written about this concept. _
Similar Concepts
People who have written about this concept.
_
Top Journals
Top journals in which articles about this concept have been published.
|